Richard Glennon

Last updated
Richard Glennon
BornJuly 1945 (age 79)
Alma mater Northeastern University (B.S., M.S.); University at Buffalo (Ph.D., postdoc)
Occupation(s) Medicinal chemist; Professor
Years active1973–present
Employer Virginia Commonwealth University
Website https://pharmacy.vcu.edu/directory/glennon-richard.html

Richard A. Glennon is an American medicinal chemist who studies psychedelics, stimulants, entactogens, and other psychoactive drugs. [1] [2] [3] He has been an important pioneer of the use of animal drug discrimination tests in scientific research for studying psychoactive drugs like hallucinogens. [4] [2] [3] Glennon has also done a large amount of work on the structure–activity relationships of psychedelics. [5] In addition, he played an important role in the discovery that the hallucinogenic effects of psychedelics are mediated by activation of serotonin 5-HT2 receptors. [4] [2] [6] [7] He is one of the most widely cited scientists in his field. [8] Glennon was the editor-in-chief of the journal Medicinal Chemistry Research from 1992 to 2002. [9] He retired in 2022 but has continued to publish reviews and research since then. [9]

Contents

Selected publications

See also

References

  1. ↑ Geyer MA (May 2024). "A Brief Historical Overview of Psychedelic Research". Biol Psychiatry Cogn Neurosci Neuroimaging. 9 (5): 464–471. doi:10.1016/j.bpsc.2023.11.003. PMID   38000715.
  2. 1 2 3 Fordyce BA, Roth BL (February 2024). "Making Sense of Psychedelics in the CNS". Int J Neuropsychopharmacol. 27 (2). doi:10.1093/ijnp/pyae007. PMC   10888522 . PMID   38289825. In 1983, Richard Glennon and colleagues identified psychedelic-induced behaviors by mescaline and LSD that were subsequently blocked by antagonists ketanserin and pirenperone in rats (Glennon et al., 1983a). From this, serotonin (5-HT) 5-HT2 receptors were suspected as primary contributors to these affects. [...] In 1983, Glennon and colleagues provided an in-depth review of the [drug discrimination (DD) paradigm, referencing numerous studies using the DD paradigm to assess both interoceptive cues and relative potencies of different psychoactive compounds (Glennon et al., 1983b).
  3. 1 2 Pellerin, C.; Seefelt, E.; Crumb, R. (1998). Trips: How Hallucinogens Work in Your Brain. Seven Stories Press. pp. 9, 81–85, 112. ISBN   978-1-888363-34-0 . Retrieved 5 February 2025.
  4. 1 2 Nichols DE (February 2004). "Hallucinogens". Pharmacol Ther. 101 (2): 131–181. doi:10.1016/j.pharmthera.2003.11.002. PMID   14761703. Table 1 gives a comparison of human dosages for several compounds where drug discrimination data in LSD-trained rats also have been obtained from the author's laboratory. Although there are several other hallucinogens that have been characterized using the drug discrimination paradigm, particularly by Richard Glennon and his colleagues, different training drugs have been used. [...] The earliest hypothesis that hallucinogenic drugs acted specifically at 5-HT2 receptor subtypes was proposed by Glennon et al. (1983c) based on drug discrimination studies in rats showing that the 5-HT2 antagonists ketanserin and pirenperone blocked the discriminative stimulus effects of phenethylamine and tryptamine hallucinogens, including LSD (Colpaert et al., 1982; Leysen et al., 1982; Colpaert & Janssen, 1983). Earlier studies (Browne & Ho, 1975; Winter, 1975) had also shown that the discriminative stimulus of mescaline was blocked by 5-HT antagonists that later were recognized to block 5-HT2 receptors.
  5. ↑ Olson DE (April 2021). "The Promise of Psychedelic Science". ACS Pharmacol Transl Sci. 4 (2): 413–415. doi:10.1021/acsptsci.1c00071. PMC   8033768 . PMID   33860170. Collectively, the SAR studies in this issue add to the large body of work by David Nichols, Richard Glennon, and others, investigating how the structures of psychedelics lead to their hallucinogenic effects.6−8
  6. ↑ López-Giménez JF, González-Maeso J (2018). "Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways". Curr Top Behav Neurosci. 36: 45–73. doi:10.1007/7854_2017_478. PMC   5756147 . PMID   28677096. The role of the 5-HT2A receptor in the mechanism of action of hallucinogens was first proposed by Richard Glennon, Milt Titeler and their teams (Glennon et al. 1984, 1986). However, it was not until the development of 5-HT2A knockout mice in 2003 that the fundamental role of 5-HT2A receptor-dependent signaling in the cellular and behavioral effects of hallucinogens was verified conclusively (Gonzalez-Maeso et al. 2003 2007).
  7. ↑ Jacobs, Barry L. (1987). "How Hallucinogenic Drugs Work: Hallucinogenic drugs appear to exert their effects by acting on a specific type of serotonin receptor in the brain". American Scientist. 75 (4). Sigma Xi, The Scientific Research Society: 386–392. ISSN   0003-0996. JSTOR   27854718 . Retrieved 5 February 2025.
  8. ↑ Komornik, Emily (31 October 2024). "New listing of the world's most-cited scientists includes 11 VCU faculty". School Of Pharmacy. Retrieved 5 February 2025.
  9. 1 2 Jones, Charles B.; Dukat, Małgorzata (3 March 2022). "Special Issue in honor of former Editor-in-Chief Prof. Richard Glennon". SpringerLink. Retrieved 5 February 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.